Every material Form 8-K Adicet Bio, Inc. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Adicet Bio reported a third-quarter 2026 net loss of $18.9 million, or $1.76 per share, compared with a net loss of $26.9 million, or $4.72 per share, in the same period of 2025. The company said its cash, cash equivalents and short-term investments of $100.9 million as of September 30, 2026, are expected to fund operating expenses into the second half of 2027.
Net loss of $18.9 million, or $1.76 per share, for the quarter ended September 30, 2026, versus $26.9 million, or $4.72 per share, a year earlier
R&D expenses fell to $15.6 million from $22.9 million, and G&A expenses fell to $4.2 million from $5.1 million
Cash, cash equivalents and short-term investments were $100.9 million on September 30, 2026, down from $158.5 million on December 31, 2025
Company expects current cash to fund operating expenses into the second half of 2027
Adicet Bio reported preliminary Phase 1 data for prula-cel, an investigational cell therapy, in 22 efficacy-evaluable patients with systemic lupus erythematosus, with or without lupus nephritis, using an August 28, 2026 data cut-off. The company plans to start pivotal study start-up activities for lupus nephritis in the fourth quarter of 2026, and the filing says the high DORIS remission rate may support including lupus patients without nephritis. The data are early, from a small group, and the filing contains no revenue or cash figures.
22 efficacy-evaluable patients (16 with lupus nephritis, 6 with extra-renal SLE); follow-up ranged from 6 to 21 months; data cut-off August 28, 2026.
At 12 months, 50% of evaluable lupus nephritis patients achieved a complete renal response and 54% of evaluable patients achieved DORIS remission.
Among 24 safety-evaluable patients, no cytokine release syndrome above Grade 2 was reported; Grade 1 or 2 CRS occurred in 25%; infections occurred in 54%, with Grade 3 or higher in 8.3%.
Pivotal lupus nephritis study start-up activities are planned for Q4 2026; a mid-2027 clinical data update in LN/SLE is anticipated.
Adicet Bio posted a September 2026 investor presentation to its website and furnished it as Exhibit 99.1 to a Form 8-K. The deck covers its prula-cel autoimmune program, its ADI-212 solid tumor candidate and its in vivo CAR-T pipeline, and sets out expected clinical and regulatory milestones.
ADI-212 has an IND cleared in the US, with first-patient dosing anticipated in 4Q26 and clinical data expected in 1H27 and 2H27.
Prula-cel clinical data cited in the deck has a cut-off date of August 31, 2025 and covers 7 patients (5 LN and 2 SLE) with follow-up of 2-9 months.
The filing describes a CRISPR license for ADI-212 gene-editing technology, with CRISPR holding an opt-in right to a 50/50 cost and profit split.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Adicet Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →